Research continues for patients:

Striving to Step Up Her Future 1L Treatment Options for HR+/HER2+ mBC

Up your understanding of HR+/HER2+ mBC

1L=first-line; HR+=hormone receptor-positive; HER2+=human epidermal growth factor receptor 2-positive; mBC=metastatic breast cancer.

HR+/HER2+ subtype accounts for approximately
10% of all breast cancers.
This subtype is associated with poorer prognoses than some other tumor types.1

Key Facts About HR+/HER2+ mBC

Additional Terminology

HR+/HER2+ is sometimes referred to as triple-positive* or double-positive breast cancer.2,3

It’s Distinct

HR+/HER2+ breast cancer is a subtype distinguished by the presence of two biomarkers that drive the disease.1

Clinical Studies

Historically, there have not been many studies specifically for patients with the HR+/HER2+ subtype, which has limited knowledge for these patients.1

Continued understanding of the triple-positive subtype may lead to different approaches for management strategy and improved patient experience.1

Unique Tumor Biology

HR+/HER2+ mBC is associated with bidirectional crosstalk between the HR and HER2 pathways. This phenomenon, known as “crosstalk,” can lead to single pathway resistance, resulting in disease progression despite initial treatment effect.2

Clinical Opportunity

Patients diagnosed with HR+/HER2+ mBC eventually experience disease progression. Historically, survival rates remain around 46% at 5 years after diagnosis. Additional research is needed in the effort to address limitations of current options for patients with an HR+/HER2+ mBC diagnosis.2,5
Style
what-to-know

*Hormone receptor status is sometimes subdivided into estrogen receptor status and progesterone receptor status. Thus, ER+/PgR+/HER2+ breast cancer may be referred to as “triple-positive,” and HR+/HER2+ breast cancer may be referred to as “double-positive.”2,3

ER+=estrogen receptor-positive; PgR+=progesterone receptor-positive.

Style
default-section

Let’s Talk About Crosstalk in HR+/HER2+ mBC

HR, particularly ER, and HER2 are the two most common drivers in breast cancer. Bidirectional crosstalk between HR and HER2 pathways can lead to continued tumor proliferation when one pathway is leveraged to compensate for the other. Therefore, crosstalk may result when both receptors are upregulated.1,2,4

While progress has been made in the management of HR+/HER2+ mBC, research is ongoing in the hope of finding different approaches that inhibit both the HR and HER2 signaling pathways. Find out more about the complexities of HR+/HER2+ mBC and crosstalk below.2,3

video_id
6365589454112
account_id
1852113022001
autoplay
false
loop
false
poster
Style
lets-talk

Hear the Experts’ Perspectives

In this three-chapter video series, breast cancer oncologists and Drs. Thomas Bachelot, Wolfgang Janni, Cristina Saura, and Debu Tripathy, discuss crosstalk and disease challenges in HR+/HER2+ mBC. In chapter 1, they discuss unmet needs for patients with HR+/HER2+ mBC. In chapter 2, they explore HR+/HER2+ mBC disease mechanisms. In chapter 3, they examine the current and future clinical landscape.

Chapter 1

Unmet needs for patients with HR+/HER2+ mBC


Drs. Bachelot, Janni, Saura, and Tripathy discuss the unique biological features of HR+/HER2+ mBC and what unmet needs patients face.

Drs. Bachelot, Janni, Saura, and Tripathy discuss the unique biological features of HR+/HER2+ mBC and what unmet needs patients face.

6379627334112

Chapter 2

HR+/HER2+ mBC disease mechanisms

They discuss crosstalk, its implications, and how well understood it is, as well as the effects of crosstalk escape mechanisms.

They discuss crosstalk, its implications, and how well understood it is, as well as the effects of crosstalk escape mechanisms.

6379625420112

Chapter 3

Current and future clinical landscapes in HR+/HER2+ mBC

Our experts discuss the current landscape and what the future looks like for patients with HR+/HER2+ mBC.

Our experts discuss the current landscape and what the future looks like for patients with HR+/HER2+ mBC.

6379622051112
Style
hear
Kay C, Martinez-Peréz C, Meehan J, et al. Current trends in the treatment of HR+/HER2+ breast cancer. Future Oncol. 2021;17(13):1665-1681.
Thanopoulou E, Khader L, Caira M, et al. Therapeutic strategies for the management of hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) breast cancer: a review of the current literature. Cancers (Basel). 2020;12(11):3317.
Pegram M, Pietras R, Dang CT, et al. Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer. Ther Adv Med Oncol. 2023;15:17588359231187201.
Giuliano M, Trivedi MV, Schiff R. Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications. Breast Care (Basel). 2013;8(4):256-262.
Cancer stat facts: female breast cancer subtypes. SEER. Accessed November 2024. https://seer.cancer.gov/statfacts/html/breast-subtypes.html